Patent EP0473564A1 successfully refreshed from Google Patents.
EP0473564A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anticoagulant combination of laci and sulfated polysaccharides
Assignee: Monsanto Co
•
Filing: 1991-08-26
•
Granted: —
•
Expires: 2011-08-26
Abstract
Abstract There is disclosed herein a combination of lipoprotein-associated coagulation inhibition (LACI) and sulfated polysaccharides, e.g. heparin, which exerts a synergistic anticoagulant action in whole plasma.
Inventors
- 👤 Tze-Chein Wun
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 20:07
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/81; C07K14/8107; C07K14/811; C07K14/8114; A; A61; A61K; A61K38/00; A61K38/16; A61K38/55; A61K38/57; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
26 words
A composition comprising lipoprotein-associated coagulation inhibitor and an anticoagulant sulfated polysaccharide in proportions that provide a synergistic anticoagulation effect upon administration to a warm blooded mammal.
Claim 2
Dependent Claim
27 words
The composition of Claim 1 in which the sulfated polysaccharide is selected from the group consisting of heparin, pentosan polysulfate, dermatan sulfate, dextran sulfate and heparan sulfate.
Claim 3
Dependent Claim
39 words
The composition according to claim 1 in which lipoprotein-associated coagulation inhibitor and heparin are in proportions of from about 0.1 to about 4 units of heparin with from about 0.1 µg to about 5 µg of lipoprotein-associated coagulation inhibitor.
Claim 4
Dependent Claim
19 words
The composition of any of claims 1 to 3 for use as a medicament in a warm blooded mammal.
Claim 5
Dependent Claim
23 words
The composition of any of claims 1 to 3 for use in a method of inhibiting blood coagulation in a warm blooded mammal.
Claim 6
Dependent Claim
46 words
The composition of any of claims 1 to 3 for use according to Claim 5, in which the said method comprises administering from about 0.1 to about 4 units of heparin and about 0.1 µg to about 5 µg of LACI per ml of plasma treated.
Claim 7
Dependent Claim
29 words
Use of a composition as defined in any of claims 1 to 3 for the manufacture of a medicament suitable for inhibiting blood coagulation in a warm blooded mammal.
References Cited (Backward Citations)
EP0439442A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.